作者: Dimitrios Tryfonopoulos
DOI:
关键词: Targeted therapy 、 Breast cancer 、 Dasatinib 、 Medicine 、 Internal medicine 、 Cancer 、 Sunitinib 、 Oncology 、 Triple-negative breast cancer 、 Sunitinib malate 、 Trastuzumab
摘要: The development of Her-2 targeted therapies has improved the prognosis for patients with positive breast cancer. However, not all tumours respond to treatment antagonists. Triple negative cancers are resistant hormone and therapies. This project focused on improving response in overexpressing cancer developing effective therapy strategies triple cancer. We tested a number multi-target kinase inhibitors (imatinib, sunitinib, pazopanib dasatinib) cell lines, alone combination other agents. Two lines showed moderate sensitivity sunitinib malate. Combined trastuzumab compared either drug alone, four tested. Dasatinib inhibited growth 3 5 but only 1 4 tested. Based inhibitors, which have overlapping target specificities, Src,PP2, our results suggest that dasatinib is due inhibition ephrin type A receptors. Consistent this hypothesis, neither Src expression nor phosphorylation predicted dasatinib, high levels Ephrin receptor 2 protein correlated sensitivity. High caveolin also panel lines. Dasatinib combined cisplatin was synergistic three dasatinib-sensitive lines. Dasatinib, 5’-deoxy-5’-fluoruridine, displayed synergy or additivity. Moderate observed docetaxel two In conclusion, we identified as rational testing triple-negative cancer, putative predictive biomarkers (EphA2, CAV1 CAV2).